Remove 2012 Remove Clinic Remove IT Remove Medical
article thumbnail

Medical Manpower Indicators: Are policymakers using poor surrogate indicators of access to Family Doctor services ? [Economic or policy analysis]

Annals of Family Medicine

Medical Manpower Indicators: Are policymakers using poor surrogate indicators of access to Family Doctor services ? In 2012, the Quebec Ministry of Health and Social Services (MSSS) reported that the population of Montreal consumed the services of 1,663 family doctors (FTE consumed). Some may be retired or working elsewhere.

article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

FDA Law Blog

Gibbs & Ana Loloei & Véronique Li, Senior Medical Device Regulation Expert — FDA has long touted the use of real-world evidence ( RWE ). RWE is “the clinical evidence regarding the usage, and potential benefits or risks, of a medical product derived from analysis of RWD.” By Jeffrey N.

Medical 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

An Escape Fire for Healthcare

Noreta Family Medicine

An Escape Fire for Healthcare I recently watched a film, called “ Escape Fire: The Fight to Rescue American Healthcare, ” a 2012 documentary about how the priorities in the US healthcare system are focused on increasing revenue, instead of on goals that improve health, like preventive care.

article thumbnail

Episode 176: Antiracism in Medicine Series – Episode 8 – Towards Justice and Race Conscious Medicine

The Clinical Problem Solvers

The answer to this question may not be easily answered and may not always be found in the clinical setting. However it is important to remember that this political invention DOES affect biology because of the way that it creates social inequity. Pearls: “Genetics is not the end all be all of understanding disease” – Dorothy E.

article thumbnail

FDA’s Issues Draft Guidance on Accelerated Approval: A Substantial Evidentiary and Procedural Overhaul to this High-Profile Pathway

FDA Law Blog

Since that time, it was formalized in FDA regulations (21 CFR 314 Subpart H) in 1992, codified in the Food, Drug, & Cosmetic Act by FDAMA (21 USC 356(c)) in 1997, revised by FDASIA in 2012, and described in guidance, most importantly, in the 2014 Expedited Programs for Serious Conditions Drugs and Biologics (2014 Guidance).

Clinic 64
article thumbnail

Through with Breakthrough? FDA’s New Draft Guidance Reflects an Uptick in Notices of Intent to Rescind

FDA Law Blog

Breakthrough Therapy Designation (BTD) was created in 2012 as part of the FDA Safety & Innovation Act (FDASIA). For CDER specifically, the division must discuss the proposed rescission with CDER’s Medical Policy Council prior to notifying the sponsor.

IT 52
article thumbnail

Surely You Must be Kidding, PTO?!? “No, and Don’t Call Me Shirley!” – The Seemingly Slapstick (But Yet Unfunny) World of Recent Patent Term Extension Decisions (PART 2)

FDA Law Blog

As FDA explains on its website (which includes lists— here and here —of the more than 300 Accelerated Approvals (and withdrawals)): The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint. That did not happen.

Clinic 59